Comparison tool

Chonluten vs Cortagen side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

ChonlutenCortagen

Share this peptide comparison

Property	Chonluten	Cortagen
Category	Bioregulators	Bioregulators
Also known as	Glu-Asp-Gly, EDG	Ala-Glu-Asp-Pro, AEDP
FDA approved	No	No
Clinical status	Preclinical research; reported supplement approval in Russia; not FDA or EMA approved Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	Preclinical research; source also reports approval in Russia as a supplement Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Respiratory health, lung function, bronchial support	Brain function, cognitive support, neuroprotection
How it works	Chonluten is presented under the Khavinson bioregulator framework, where short peptides are proposed to enter cells and influence nuclear gene-expression activity. For Chonluten specifically, the source links the hypothesis to respiratory epithelial tissue and genes related to stress response, antioxidant activity, and inflammation. The same evidence cautions that this remains a proposed mechanism, with uncertainty about whether free EDG reaches human nuclei at relevant concentrations or binds specific DNA regions in a clinically meaningful way.	Cortagen is presented as part of the Khavinson short-peptide bioregulator model. The source describes a hypothesis in which small peptides can reach the cell nucleus and associate with DNA and histone proteins, potentially influencing gene expression instead of signaling primarily through a membrane receptor. For Cortagen, the proposed tissue focus is the brain cortex and neuronal repair biology. The source cautions that this peptide-DNA concept remains a hypothesis from a limited research lineage and has relatively thin independent validation.
Typical dosing	10-20 mg daily · Once or twice daily	10-20 mg daily · Once or twice daily
Research dosing	10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual	10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual
Typical duration	10-30 day cycles	10-30 day cycles
Administration	Oral capsules or sublingual	Oral capsules or sublingual
Timing	Morning on an empty stomach Take on an empty stomach	Morning on an empty stomach Take on an empty stomach
Evidence level	Preclinical	Preclinical
Possible side effects	Generally well tolerated in the source report (The source does not provide detailed adverse-event rates or controlled safety data.) Limited safety data outside Russia (Safety generalizability is uncertain because the source highlights limited data beyond Russian research settings.) Not FDA approved (Regulatory non-approval is safety context, not a specific adverse effect.)	Generally well tolerated (Reported by the source, but detailed safety data are limited.) Limited safety data outside Russia (The source flags this as an evidence limitation.) Not FDA approved (This is a regulatory limitation listed by the source, not a physiological side effect.)
Research summary	The supplied source connects Chonluten, the EDG tripeptide, to Khavinson-group work on bronchopulmonary tissue. It reports discussion of oral EDG in chronic bronchitis with an asthmatic component and mentions related work pairing EDG with Bronchogen in chronic obstructive pulmonary disease contexts. The evidence base is described as concentrated in one research network, with uncontrolled clinical observations, limited independent replication, no registered randomized controlled trials, and mechanistic claims relying on cell-culture or animal findings rather than confirmed human outcomes.	The source highlights a rat sciatic-nerve injury experiment in which intramuscular Cortagen at 10 micrograms per kilogram for 10 days was associated with faster regenerating fiber growth and higher conduction velocity after nerve cutting and suturing. It also cites a Khavinson organ-culture paper reporting selective stimulation of rat brain cortex explants. Other described evidence includes small in vitro or animal studies from the same research environment, including gene-expression and aging-model work. The source does not identify Western randomized controlled human trials for cognition, neuroprotection, or other outcomes, so the overall evidence base remains preliminary.
References	Source Source +2 more Source Source	PubMed PubMed +3 more SpringerLink MDPI Molecules PubMed Central
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Chonluten

Cortagen

Category

Bioregulators

Also known as

Glu-Asp-Gly, EDG

Ala-Glu-Asp-Pro, AEDP

FDA approved

Clinical status

Preclinical research; reported supplement approval in Russia; not FDA or EMA approved

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

Preclinical research; source also reports approval in Russia as a supplement

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Respiratory health, lung function, bronchial support

Brain function, cognitive support, neuroprotection

How it works

Chonluten is presented under the Khavinson bioregulator framework, where short peptides are proposed to enter cells and influence nuclear gene-expression activity. For Chonluten specifically, the source links the hypothesis to respiratory epithelial tissue and genes related to stress response, antioxidant activity, and inflammation. The same evidence cautions that this remains a proposed mechanism, with uncertainty about whether free EDG reaches human nuclei at relevant concentrations or binds specific DNA regions in a clinically meaningful way.

Cortagen is presented as part of the Khavinson short-peptide bioregulator model. The source describes a hypothesis in which small peptides can reach the cell nucleus and associate with DNA and histone proteins, potentially influencing gene expression instead of signaling primarily through a membrane receptor. For Cortagen, the proposed tissue focus is the brain cortex and neuronal repair biology. The source cautions that this peptide-DNA concept remains a hypothesis from a limited research lineage and has relatively thin independent validation.

Typical dosing

10-20 mg daily · Once or twice daily

Research dosing

10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual

Typical duration

10-30 day cycles

Administration

Oral capsules or sublingual

Timing

Morning on an empty stomach

Take on an empty stomach

Morning on an empty stomach

Take on an empty stomach

Evidence level

Preclinical

Possible side effects

Generally well tolerated in the source report (The source does not provide detailed adverse-event rates or controlled safety data.)
Limited safety data outside Russia (Safety generalizability is uncertain because the source highlights limited data beyond Russian research settings.)
Not FDA approved (Regulatory non-approval is safety context, not a specific adverse effect.)

Generally well tolerated (Reported by the source, but detailed safety data are limited.)
Limited safety data outside Russia (The source flags this as an evidence limitation.)
Not FDA approved (This is a regulatory limitation listed by the source, not a physiological side effect.)

Research summary

The supplied source connects Chonluten, the EDG tripeptide, to Khavinson-group work on bronchopulmonary tissue. It reports discussion of oral EDG in chronic bronchitis with an asthmatic component and mentions related work pairing EDG with Bronchogen in chronic obstructive pulmonary disease contexts. The evidence base is described as concentrated in one research network, with uncontrolled clinical observations, limited independent replication, no registered randomized controlled trials, and mechanistic claims relying on cell-culture or animal findings rather than confirmed human outcomes.

The source highlights a rat sciatic-nerve injury experiment in which intramuscular Cortagen at 10 micrograms per kilogram for 10 days was associated with faster regenerating fiber growth and higher conduction velocity after nerve cutting and suturing. It also cites a Khavinson organ-culture paper reporting selective stimulation of rat brain cortex explants. Other described evidence includes small in vitro or animal studies from the same research environment, including gene-expression and aging-model work. The source does not identify Western randomized controlled human trials for cognition, neuroprotection, or other outcomes, so the overall evidence base remains preliminary.

References

Source Source

+2 more

Source Source

PubMed PubMed

+3 more

SpringerLink MDPI Molecules PubMed Central

Full profile

View Details